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Comparative Cytotoxicity of Artemisinin and Cisplatin and
Their Interactions with Chlorogenic Acids in MCF7 Breast
Cancer Cells
John O. Suberu,[b] Isolda Romero-Caneln,[c] Neil Sullivan,[d] Alexei A. Lapkin,[b] and
Guy C. Barker*[a]
Introduction
Cancer is a major public health problem with about 7.6 million
deaths in 2008; this number is projected to increase to over 13
million in 2030.[1] Although a range of treatment options are
available, in many cases these therapies are fraught with signif-
icant levels of toxicity to healthy cells, and drug resistance
quickly develops in some treatment regimes. To decrease the
current cancer burden, drug discovery is directed at the devel-
opment of highly effective and potent medications with re-
duced side effects.
Natural products are a rich source of active principles
against cancer cells. A major success of pharmacognosy is the
isolation of paclitaxel (Taxol) from the bark of the Pacific yew
tree (Taxus brevifola). Paclitaxel exerts its anticancer effect by
inhibiting mitosis and is now a drug approved by the US Food
and Drug Administration (FDA) for ovarian and breast can-
cers.[2] Another success is the antimalarial compound artemisi-
nin (1), a sesquiterpene lactone derived from Artemisia
annua L. that possesses a unique trioxane bridge (Figure 1).
The in vitro cytotoxic activity of artemisinin and its deriva-
tives has been reported in various cancer cell lines, including
drug-resistant lines.[3] Sigh and Lai showed that a combination
In parts of Africa and Asia, self-medication with a hot water in-
fusion of Artemisia annua (Artemisia tea) is a common practice
for a number of ailments including malaria and cancer. In our
earlier work, such an extract showed better potency than arte-
misinin alone against both chloroquine-sensitive and -resistant
parasites. In this study, in vitro tests of the infusion in MCF7
cells showed high IC50 values (>200 mm). The combination of
artemisinin and 3-caffeoylquinic acid (3CA), two major compo-
nents in the extract, was strongly antagonistic and gave a near
total loss of cytotoxicity for artemisinin. We observed that the
interaction of 3CAs with another cytotoxic compound, cispla-
tin, showed potentiation of activity by 2.5-fold. The chelation
of cellular iron by 3CA is hypothesized as a possible explana-
tion for the loss of artemisinin activity.
Figure 1. Structures of some compounds found in Artemisia aqueous extract
(tea) and cisplatin.
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of dihydroartemisinin (5) and holotransfferin effectively kills ra-
diation-resistant breast cancer cells,[3b] while artemisinin pre-
treated with holotransfferin was also found to be effective
toward both drug-sensitive and multi-drug-resistant human
lung carcinoma (SCLC) cells.[3c] Artesunate (6) inhibited the
growth of highly angiogenic Kaposi sarcoma cells, showing the
anti-angiogenesis effect of artemisinins.[4] In their study, Chen
et al. implanted nude mice with human ovarian cancer cells
and found that artesunate decreased tumor growth and signif-
icantly lowered vascular endothelial growth factor (VEGF) ex-
pression in the cells.[5] The potential of artemisinin to prevent
the development of breast cancer in rats treated with a known
carcinogen (7,12-dimethylbenz[a]anthracene, DMBA) has been
reported.[6] Artesunate has also been successfully used in com-
bination with standard chemotherapy to treat metastatic mela-
noma in human subjects after standard chemotherapy alone
was ineffective in stopping tumor growth.[7]
Artemisinin and its derivatives have also been used as che-
mosensitizers for conventional treatments in drug-resistant
cancer cell lines.[8] Synergistic interaction of dihydroartemisinin
with gemcitabine, a cancer drug, showed a 45% enhancement
in tumor growth inhibition compared with the drug alone.[9]
The improved efficacy of multicomponent combinations in-
volving artemisinin in cancer treatment has encouraged inves-
tigation of other natural compounds besides artemisinin that
may exhibit individual cytotoxic activity or that can be poten-
tial artemisinin synergists in the crude extract. Two artemisinin-
related compounds, artemisitene (2) and arteannuin B (4), and
two unrelated ones, scopoletin and 1,8-cineole, have shown
antiproliferative activity.[10] No cross-resistance to artemisinin
was observed with any of these actives, thus showing a poten-
tial for use in combination to treat drug-resistant tumors.
In the artemisinin research community, a significant degree
of interest has been focused on the activity of aqueous ex-
tracts (Artemisia tea).[11] This interest stems largely from the
widely reported use of Artemisia aqueous infusions in folk
medicine. Through in vitro tests, we recently showed that
some constituents of the extract interact synergistically with
artemisinin, resulting in increased antiplasmodial activity.[12]
Consequently, we were interested in the interactions of artemi-
sinin with co-metabolites in the extract, in view of improved
cytotoxicity.
Carbonara et al. observed that the major constituents of Ar-
temisia tea are chlorogenic acids (11–17).[13] They also detected
a number of feruloylquinic acids together with some flavo-
noids in the extract. Chlorogenic or caffeoylquinic acids (CQAs)
are esters of caffeic (10) and quinic acids. The pharmacological
properties of these catechols include antioxidant, hepatopro-
tectant, antibacterial, antihistiminic, chemopreventive, and
other biological effects.[14] Lee and Zhu showed that chloro-
genic acids and other catechol-containing dietary polyphenols
can inhibit the methylation of synthetic DNA substrates in
vitro and can inhibit the methylation of the promoter region
of the RAb gene in human breast cancer cells ; both are nor-
mally hypermethylated in neoplastic cells.[15] In their study, Nor-
atto et al. showed the chemopreventive potential of dietary
chlorogenic and neochlorogenic acids.[16] These compounds ex-
erted relatively high growth inhibition on the estrogen-inde-
pendent breast cancer cell line and low toxicity in normal cells.
Chlorogenic acid derivatives were also found to inhibit hepato-
cellular carcinoma cell line proliferation and induced apoptosis
in leukemia cell lines.[17]
This study was therefore undertaken to evaluate the in vitro
cytotoxicity toward breast cancer cells of Artemisia tea and ar-
temisinin in combination with co-metabolites present in the
tea extract. It specifically looks at the interaction of artemisinin
with chlorogenic acid (3-caffeoylquinic acid, 3CA) to assess
possible implications for the use of Artemisia tea in cancer
therapy and compares this with cisplatin’s interaction with 3CA
in MCF7 cells.
Results and Discussion
The metabolite profile and cytotoxic activity of Artemisia hot
water infusion (tea) in MCF7 breast cancer cells was evaluated
and compared with the activity of artemisinin alone and in
combination with chlorogenic acid, a co-metabolite in the ex-
tract. A combination study of chlorogenic acid with the drug
cisplatin [cis-diamminedichloroplatinum(II)] was carried out for
comparative analysis and possible elucidation of the interac-
tions in Artemisia tea extract.
Composition of Artemisia tea
The profile of metabolites in aqueous extract is listed in
Table 1. These were analyzed by both MS–MS and HPLC meth-
ods. The profiling is based on the extensive analysis by Carbo-
nara et al.[13] and on our earlier work[18] with artemisinin-related
compounds in the extracts.
The levels of artemisinin reported in the tea extracts are
varied and the values obtained in this study (47.50.8 mgL1)
are within that range. This corresponds to about 16% of clini-
cal exposure to the drug in reported treatment regimes, which
also showed that the bioavailability of artemisinin in tea is very
similar to pure artemisinin administered as a capsule.[13,19]
Van der Kooy and Verpoorte[19a] have shown that the method
Table 1. Metabolites in the aqueous Artemisia extract analyzed by both
MS–MS and HPLC methods.
Compound Amount [mg (L tea)1][a]
artemisinin 47.500.80
arteannuin B 1.300.01
caffeic acid 0.800.03
3,5-dicaffeoylquinic acid 57.001.70
3-caffeoylquinic acid 72.001.60
4-caffeoylquinic acid 20.401.60
4,5-dicaffeoylquinic acid 31.604.00
5-caffeoylquinic acid 9.000.70
isovitexin 65.007.20
rosmarinic acid 1.100.01
[a] Values are the meanSD of n=2 determinations of triplicate meas-
urements.
 2014 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2014, 9, 2791 – 2797 2792
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employed in preparing the hot water infusion does affect the
amount of artemisinin and other co-metabolites extracted. This
study, as well as others,[19a,b] used the therapeutically recom-
mended ratio of 1:200 w/v or 5 gL1.[20] Arteannuin B (5)
(1.3 mgL1), a biosynthetic precursor of artemisinin, was also
detected in the tea extract using our method.[18]
The most abundant of the caffeic derivatives 11–17 was 3-
caffeoylquinic acid (11) (72 mgL1) in the analyzed extract, fol-
lowed by 3,5-dicaffeoylquinic acid (15) (57 mgL1). A compara-
tively lower amount (0.8 mgL1) was observed for caffeic acid
(10). The only flavonoid analyzed was isovitexin (8) (65 mgL1)
and was relatively abundant in our extract. Rosmarinic acid (9)
was lower (1.1 mgL1) in our samples than the levels found by
de Magalh¼es and co-workers.[19c]
Cytotoxicity of cisplatin, artemisinin, and 3CA
Table 2 shows the 50% inhibitory concentration for artemisinin,
cisplatin and 3CA in MCF7 breast cancer cells. This cell line is
derived from breast adenocarcinoma tissues and is a common
model employed in carcinogenesis and chemopreventive stud-
ies.[21]
Cytotoxicity of artemisinin
The cytotoxicity of artemisinin (Table 2 and Figure 2) in the
MCF7 cells shows it to be potent against invasive breast ductal
carcinoma that is estrogen sensitive. The IC50 values obtained
for the compound (9.130.07 mm) are within a range of values
(IC50 0.17–87.10 mm) reported by Efferth and Oesch for artemisi-
nin and its derivatives determined for the tumor panel of 60
cell lines of the National Cancer Institute (NCI) screening pro-
gram.[22] Artemisinin had the highest IC50 value (least potent) of
all the related derivatives reported. Artemisinin is metabolized
into dihydroartemisinin (DHA), which has a lower IC50 value
(2.3 mm) in MCF7 cells[22,23]
Several researchers have investigated the mechanism of se-
lective cytotoxicity of artemisinin and its derivatives toward
neoplastic cells. Mercer et al. showed that selective activation
of the trioxane bridge via carbon-centered radicals occurs in
rapidly dividing or susceptible cells.[24] This then results in mito-
chondrial membrane depolarization, leading to induction of
apoptosis by the chemical stress pathway and activation of
caspases-3 and -7 in HL-60 cells, resulting in degraded DNA or
hypodiploidy. Li et al. also showed that artemisinin derivatives
induce apoptosis mainly through G1 arrest.
[25] The G1 phase is
associated with increased iron intake and transfferin receptor
expression. Down-regulation of anti-apoptotic Bcl-2 proteins
and up-regulation of pro-apoptotic Bax proteins have been as-
sociated with artesunate-treated human vein endothelial cells.
Artemisinins have also been associated with lowered vascular
endothelial growth factor (VEGF) expression. VEGFs are potent
angiogenic factors.[26] These studies suggest that the mecha-
nism(s) for the cytotoxicity of artemisinins involves many differ-
ent pathways.
Activity of cisplatin
Cisplatin showed superior cytotoxicity in MCF7 cells compared
with artemisinin (Table 2 and Figure 3). The mean IC50 value
obtained (5.750.07 mm) is similar to values reported by Isik-
Table 2. IC50 values for artemisinin, cisplatin and 3CA in MCF7 cells.
Compound IC50 [mm]
[a]
artemisinin 9.130.07
cisplatin 5.750.02
3-caffeoylquinic acid 126.980.13
[a] Values are the meanSD of n=2 determinations of triplicate meas-
urements.
Figure 2. A dose–response curve for artemisinin in MCF7 cells. Percentage
cell survival is plotted against the logarithm of treatment concentrations.
Data points are the meansSD of duplicate determinations of triplicate
measurements.
Figure 3. An IC50 curve for MCF7 cells treated with cisplatin. Percentage cell
survival is plotted against the logarithm of treatment concentrations. Data
points are the meansSD of duplicate determinations of triplicate measure-
ments.
 2014 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2014, 9, 2791 – 2797 2793
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dag et al. (IC50 8.6 mm) using MCF7 cells and the same duration
of drug exposure.[27] Although cisplatin is very effective with
solid-type carcinoma, drug resistance and toxic side effects
have also been reported.[28]
As a platinum-based drug, cisplatin (7) exerts its cytotoxic
effect through multiple mechanisms of which the most impor-
tant and the best understood involves interaction with DNA to
form GG intrastrand DNA cross-links, leading to the activation
of several signal transduction pathways and culminating in the
induction of mitochondrial apoptosis.[29] Consistent initial re-
sponses have been obtained by cisplatin treatment. However,
these often result in the development of chemoresistance and
therapeutic failure.[30] The combination of cisplatin with a che-
mosensitizer or a synergist can potentially improve efficacy
and restore sensitivity to cisplatin.[31]
Cytotoxicity of 3CA
The IC50 for 3CA in MCF-7 cells (127.00.8 mm) was highest
among the three single agents tested (Figure 4). This is similar
to the observation by Lee et al. , who reported that the growth
inhibition of MCF-7 cells by 3CA was insignificant up to 20 mm
and only inhibited by about 15% at 50 mm concentration.[15a]
Therefore, 50% growth inhibition at a concentration of 126.9
0.1 mm, which we obtained, is in the range of the reported
values. The chemopreventive and antiproliferation effects of 3-
caffeoylquinic acid along with other dietary derivatives have
also been reported.[16,17]
The cytotoxicity of 3CA is dose dependent and is observable
only above a certain concentration.[15a] Controversial and con-
flicting experimental results have been observed[32] in trials in-
volving endogenous antioxidants such as 3CA because of their
“double-edged sword” effect at cellular redox sites. Depending
on the dosage level and the in situ matrix, these compounds
can either be pro-oxidative or antioxidative.
Cytotoxicity of Artemisia tea
The dose–response for Artemisia tea is shown in Figure 5. Sev-
eral repeat analyses gave values above 200 mm. The high IC50
values observed with tea and the complex composition of the
same necessitated examination of the interactions among
fewer metabolites. The combination of artemisinin with 3CA
was subsequently investigated. In our analysis of the tea, 3CA
was one of the most abundant components, second only to
isovitexin (Table 1). Our choice of 3CA was also informed by its
prominent dietary profile.
Cytotoxic combination studies
The cytotoxicity of Artemisia tea was investigated to assess its
possible role in cancer therapy. The unexpectedly high IC50
value for the phyto complex led to the investigation of simpler
combinations in the extract. The combination of artemisinin
and 3CA resulted in a drastic modification of artemisinin’s ac-
tivity (Table 3). Consequently, we investigated the interaction
of 3CA with cisplatin to see if a similar effect is reproduced in
another anticancer drug.
The combination of caffeic and chlorogenic acids with che-
motherapeutic agents as chemosensitisers has been reported.
An increased sensitivity of multidrug-resistant breast cancer
cells (MCF-7/Dox) to doxorubicin was observed with caffeic
Figure 5. A dose–response curve for Artemisia tea extract in MCF7 cells. Per-
centage cell survival is plotted against the logarithm of treatment concentra-
tions. Data points are the meansSD of duplicate determinations of tripli-
cate measurements.
Table 3. IC50 values for 3CA in combination with artemisinin and cisplatin
in MCF7 cells.
Compounds IC50 [mm]
[a]
artemisinin+3CA >200
cisplatin+3CA 2.270.06
[a] Values are the meanSD of n=2 determinations of triplicate meas-
urements.
Figure 4. An IC50 curve for 3CA in MCF-7 cells. Percentage cell survival is
plotted against the logarithm of treatment concentrations. Data points are
the meansSD of duplicate determinations of triplicate measurements.
 2014 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2014, 9, 2791 – 2797 2794
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acid.[33] A US patent for the use of chlorogenic acid as a sensitiz-
er for chemotherapeutic agents reported a 30% decrease in
the viability of cancer cells sensitized by chlorogenic acids to
doxorubicin compared with cells administered with doxorubi-
cin alone.[34]
Artemisinin combination with 3CA
The dose–response curve for the combination of artemisinin
and 3CA at a 1:1 molar ratio is shown in Figure 6. The IC50 in
MCF-7 cells for the combination is >200 mm. This represents
a near complete loss of cytotoxicity for the compound in the
presence of 3CA (Table 2). A similar loss of activity was ob-
served in combinations involving lower 3CA concentrations
with artemisinin (artemisinin/3CA, 1:0.5 and 1:0.01). This sug-
gests an antagonistic interaction between artemisinin and 3CA
when combined and may partly explain the high IC50 values
observed.
Cisplatin combination with 3CA
To investigate if the strong antagonistic interaction observed
for artemisinin and 3CA is reproduced in other anticancer
agents, an equimolar combination of cisplatin and 3CA was
tested. An IC50 value of 3.6 mm was obtained from the dose–
response curve (Figure 7). This represents a 2.5-fold improve-
ment in potency relative to cisplatin alone (Table 2). Kim re-
ported the chemosensitizing effect of chlorogenic acids, and
an improvement in activity of doxorubicin was observed when
combined with chlorogenic acid in a range of combinations.[34]
The mechanism for the interaction of 3CA in MCF-7 with ar-
temisinin (antagonism) and cisplatin (potentiation) seem to be
pharmacokinetic in nature, where the observed change in ac-
tivity for a combination relative to the single agent is due to
modification in the absorption, distribution, metabolism, or ex-
cretion of a compound (cisplatin and artemisinin) by another
(3CA).[35] The improvement in cytotoxicity of the combination
of cisplatin and 3CA over cisplatin alone is less likely due to
3CA cytotoxicity, which is shown to be relatively inactive
(Table 2).
The activation of artemisinin and the cleavage of the endo-
peroxide bridge to form a carbon-centered radical and/or reac-
tive oxygen species (ROS) is a key to the compound’s cytotox-
icity and antiplasmodial activities. This activation has been sug-
gested to be initiated by endogenous iron, which is relatively
abundant in actively dividing cells relative to normal cells.[3d]
Kono et al. and others reported that 3CA has iron-chelating
properties and forms a complex with the metal.[36] In a combi-
nation with artemisinin, 3CA may chelate and complex with
endogenous iron, and as a result depletes the iron pool avail-
able for the activation of artemisinin. This effect will be more
pronounced in the cytotoxic activity of artemisinin relative to
its antiplasmodial activity, because the erythrocytic iron pool is
severalfold more abundant than the neoplastic cell iron
pool.[36a]
This is consistent with our observations for the combination
in both antiplasmodial and cytotoxic assays. In the previous
work, a mild antagonism was observed for the antiplasmodial
activity of 3CA and artemisinin combination.[12] In the above
cytotoxicity assay, strong antagonism (or a near total loss of ac-
tivity) was observed (Figure 6). Williamson has reviewed similar
adverse reactions (ADRs) in herbals and the methods by which
antagonism arises in these mixtures.[37]
In contrast, cisplatin is activated in the cell by aquation of
the molecule, resulting in the loss of one or both of its chloride
ions. The activation is enhanced by a lower intracellular chlo-
ride ion concentration than its extracellular concentration.[28b]
Metal ions do not seem to play any role in cisplatin activation
and are thus unaffected by the metal-chelating properties of
3CA. It would be interesting to investigate whether cisplatin
Figure 6. A dose–response curve for MCF-7 cells treated with a combination
of artemisinin and 3CA. Percentage cell survival is plotted against the loga-
rithm of treatment concentrations. Data points are the meansSD of dupli-
cate determinations of triplicate measurements.
Figure 7. A dose–response curve for an equimolar combination of cisplatin
and 3CA. Percentage cell survival is plotted against the logarithm of treat-
ment concentrations. Data points are the meansSD of duplicate determi-
nations of triplicate measurements.
 2014 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2014, 9, 2791 – 2797 2795
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can chelate with CO2
 and deprotonated OH (six-membered
ring) of 3CA.
Conclusions
This study investigated in vitro the use of Artemisia tea as
a chemotherapeutic agent using MCF7 cells. The high IC50
value observed for the tea extract led to the investigation of
the combinations of 3-caffeoylquinic acid (3CA), a major com-
ponent of the tea, with artemisinin, the main active ingredient
in the extract. The combination showed a near total loss
(strong antagonism) of cytotoxicity. This was in contrast to
a 2.5-fold improvement observed when 3CA was combined
with cisplatin, another anticancer agent. An explanation was
suggested for these observations and also a possible reason
was advanced for the difference in antiplasmodial and cytotox-
icity of 3CA combination with artemisinin via endogenous
iron-mediated activation of the artemisinin molecule.
Based on these results, the use of Artemisia tea in cancer
therapeutics seems at best unpredictable and at worst ineffec-
tive. Further in vivo and in vitro investigations of the interac-
tions between artemisinin with 3CA and other dietary antioxi-
dants is imperative before any recommendation for the use of
artemisinin and its derivatives as antiproliferative drugs with
the possible avoidance of antioxidant food and drink immedi-
ately before and after intake of the drugs in single or combina-
tion therapies can be established.
Experimental Section
Chemicals : Artemisinin (98%), dimethyl sulfoxide (DMSO), chloro-
genic acids, trichloroacetic acid (99%), sulforhodamine B (SRB;
75%), sodium phosphate monobasic monohydrate (99%),
sodium phosphate dibasic heptahydrate (99%), acetic acid (
99%), and cisplatin were obtained from Sigma–Aldrich (Dorset,
UK). Arteannuin B was gifted by Walter Reed Army Institute of Re-
search (WRAIR) USA. LC–MS-grade formic acid in water, acetonitrile,
and HPLC-grade acetonitrile were obtained from Fisher Scientific,
UK. Purified water (~18 MWcm1) was dispensed from a Milli Q
system (Millipore, UK). For the in vitro assays, RPMI 1640 medium,
as well as fetal bovine serum, l-glutamine, a penicillin/streptomy-
cin mixture, trypsin, and phosphate-buffered saline (PBS) were pur-
chased from PAA Laboratories GmbH (Germany).
Plant materials : High-yielding dried A. annua biomass was ob-
tained from BIONEX Madagascar and stored under dark, cool con-
ditions until use.
Plant extracts : Artemisia tea was prepared according to published
methods with a slight modification.[11a,38] Briefly, 1 L of boiling
water was added to 5 g of dried plant material, stirred and stored
in the dark for 1 h. The extract was filtered in vacuo and lyophi-
lized after freezing to obtain the dried tea extract. The ethanolic
extract was obtained by sonication for 30 min in ethanol at 1:10
(w/v) biomass-to-solvent ratio. The sonication bath was kept cool
with ice, and the extract was filtered and concentrated in vacuo at
30 8C, and further dried under a gentle stream of nitrogen gas.
These extracts were used in the antiproliferation assays.
MS–MS method for artemisinins : The MS–MS method is described
in detail elsewhere.[18] Briefly, the MS–MS system was operated
with an ESI interface in positive ionization mode (ESI+). The cone
and desolvation gas flow rates were set at 45 and 800 Lh1, re-
spectively. MS parameters were automatically defined using Waters
IntelliStart software for the tuning and calibration of the TQD and
subsequently manually optimized for all analytes. Capillary voltage
was set at 2.8 kV, collision voltage at 7 V, source temperature was
150 8C, and cone voltage was set at 24 V. A multiple reaction-moni-
toring (MRM) transition of 283!219+229+247+265 was used
for artemisinin. Quantification was determined by using MRM
modes for the above transitions. The dwell time was automatically
set at 0.161 s. Data were acquired by MassLynx ver. 4.1 software
and processed for quantification with QuanLynx ver. 4.1 (Waters
Corp., Milford, MA, USA).
The HPLC system consisted of a binary pump, a cooling autosam-
pler with an injection loop of 10 mL set at 10 8C. The column heater
was set at 30 8C and a GenesisLightn C18 column (1002.1 mm,
4 mm) (Grace, IL, USA) protected by an Acquity-LC column in-line
filter unit (0.2 mm in-line frit) was used for separation of metabo-
lites. The mobile phase consisted of A: 0.1% formic acid in water
and B: 0.1% formic acid in acetonitrile used in the following gradi-
ent: 0–7.00 min, 25!98% B; 7–9.5 min, 98% B; 9.5–10 min, 98!
25% B; 10–15 min, 25% B at a flow rate of 0.4 mLmin1. Weak
wash solvent was 10% acetonitrile, strong and needle wash sol-
vent was a mixture of acetonitrile, propan-2-ol, methanol, and
water (30:30:30:10 v/v/v/v).
Cell culture : MCF7 human breast carcinoma cells were obtained
from the European Collection of Cell Cultures (ECACC) and used
between passages 5 and 18. The cells were grown in RPMI 1640
supplemented with 10% fetal calf serum, 1% 2 mm l-glutamine,
and 1% penicillin/streptomycin, as adherent monolayers at 310 K
in a 5% CO2 humidified atmosphere and passaged at approximate-
ly 70–80% confluence.
In vitro growth inhibition assays : Briefly, 5000 cells were seeded
per well in 96-well plates. The cells were pre-incubated in drug-
free media at 310 K for 48 h before adding various concentrations
of the compounds to be tested. Stock solutions of the compounds
were first prepared in 5% DMSO and a mixture 0.9% saline and
medium (1:1) following serial dilutions in RPMI 1640. The drug ex-
posure period was 24 h. After this, supernatants were removed by
suction, and each well was washed with PBS. A further 72 h was al-
lowed for the cells to recover in drug-free medium at 310 K. The
SRB assay was used to determine cell viability.[39] Absorbance meas-
urements of the solubilized dye (on a BioRad iMark microplate
reader using a 470 nm filter) allowed the determination of viable
treated cells relative to untreated controls using the inflection
point of a dose–response graph. IC50 values (concentrations that
caused 50% cell growth inhibition) were determined as duplicates
of triplicate readings in two independent sets of experiments and
their standard deviations were calculated.
IC50 modulation experiments : Experiments to investigate the
effect of co-administration of artemisinin and 3CA were carried out
as described above, with the following modifications: cells were
pre-incubated in drug-free medium for 48 h at 310 K, before
adding artemisinin together with 3CA. To prepare stock solutions
of the drug, the solid artemisinin was dissolved first in 5% DMSO
and then diluted in a 1:1 mixture of 0.9% saline and the cell cul-
ture medium. This stock was further diluted using RPMI 1640 until
working concentrations were achieved. Separately, a stock solution
of 3CA was prepared in a similar manner. Both solutions were
added to each well independently, but within 5 min of each other.
Once again the drug exposure time was 24 h and the drug-free re-
 2014 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2014, 9, 2791 – 2797 2796
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covery time was 72 h. The SRB assay was used to determine cell vi-
ability. IC50 values were determined as duplicates of triplicates in
two independent sets of experiments and their standard deviations
were calculated.
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